Evotec SE
Evotec SE (EVO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · EVO · as of Jun 8, 2026
Key Statistics
Explore Evotec SE Data
evo stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 7 · Buy rate: 57.1%
The EVO analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month price target is $7.00, representing +150.00% upside from the current price of $2.80.
Competitors & Peers
evo competitorsEVO
ALVO
AZTA
HROW
NVCR
PCRXStock Performance
Full HistoryAbout Evotec SE
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas…
what is evotec se · evo stock overview · evotec se company profile · who is evotec se ceo · evo NASDAQ · evotec se headquarters · evotec se business segments
About Stock Overview & Key Data
Evotec SE (EVO) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry, listed on NASDAQ since Feb 5, 2004. As of the latest trading session, EVO stock price is $2.80, with a market capitalization of $994.5M. The stock has returned -32.04% over the past 12 months and -9.09% year-to-date.
According to 7 Wall Street analysts, the consensus rating for Evotec SE stock is Buy, with an average 12-month price target of $7.00. In fiscal year 2025, Evotec SE reported revenue of $757.3M and net income of -$99.4M. For detailed data — including Evotec SE revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Evotec SE (EVO) stock price is $2.80. The stock is traded on NASDAQ under the ticker symbol EVO. The 52-week range is $2.31 – $4.44.